187 related articles for article (PubMed ID: 22958206)
1. Increased age of transformed mouse neural progenitor/stem cells recapitulates age-dependent clinical features of human glioma malignancy.
Mikheev AM; Ramakrishna R; Stoll EA; Mikheeva SA; Beyer RP; Plotnik DA; Schwartz JL; Rockhill JK; Silber JR; Born DE; Kosai Y; Horner PJ; Rostomily RC
Aging Cell; 2012 Dec; 11(6):1027-35. PubMed ID: 22958206
[TBL] [Abstract][Full Text] [Related]
2. A syngeneic glioma model to assess the impact of neural progenitor target cell age on tumor malignancy.
Mikheev AM; Stoll EA; Mikheeva SA; Maxwell JP; Jankowski PP; Ray S; Uo T; Morrison RS; Horner PJ; Rostomily RC
Aging Cell; 2009 Aug; 8(4):499-501. PubMed ID: 19489742
[TBL] [Abstract][Full Text] [Related]
3. Geropotency: increased malignant potential of aging neural progenitors.
Mikheev AM; Stoll EA; Ramakrishna R; Mikheeva SA; Horner PJ; Rostomily RC
Aging (Albany NY); 2012 Dec; 4(12):854-5. PubMed ID: 23257545
[No Abstract] [Full Text] [Related]
4. CD44 Interacts with HIF-2α to Modulate the Hypoxic Phenotype of Perinecrotic and Perivascular Glioma Cells.
Johansson E; Grassi ES; Pantazopoulou V; Tong B; Lindgren D; Berg TJ; Pietras EJ; Axelson H; Pietras A
Cell Rep; 2017 Aug; 20(7):1641-1653. PubMed ID: 28813675
[TBL] [Abstract][Full Text] [Related]
5. The p75 neurotrophin receptor enhances HIF-dependent signaling in glioma.
Tong B; Pantazopoulou V; Johansson E; Pietras A
Exp Cell Res; 2018 Oct; 371(1):122-129. PubMed ID: 30092219
[TBL] [Abstract][Full Text] [Related]
6. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas.
Fujiwara S; Nakagawa K; Harada H; Nagato S; Furukawa K; Teraoka M; Seno T; Oka K; Iwata S; Ohnishi T
Int J Oncol; 2007 Apr; 30(4):793-802. PubMed ID: 17332917
[TBL] [Abstract][Full Text] [Related]
7. The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells.
Park HJ; Kim JK; Jeon HM; Oh SY; Kim SH; Nam DH; Kim H
Mol Cells; 2010 Nov; 30(5):403-8. PubMed ID: 20814749
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Chen C; Han S; Meng L; Li Z; Zhang X; Wu A
PLoS One; 2014; 9(6):e100297. PubMed ID: 24937153
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma.
Di K; Lomeli N; Wood SD; Vanderwal CD; Bota DA
Oncotarget; 2016 Nov; 7(47):77457-77467. PubMed ID: 27764809
[TBL] [Abstract][Full Text] [Related]
10. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
Oh H; Hwang I; Jang JY; Wu L; Cao D; Yao J; Ying H; Li JY; Yao Y; Hu B; Wang Q; Zheng H; Paik J
Cancer Res; 2021 Mar; 81(6):1528-1539. PubMed ID: 33509942
[TBL] [Abstract][Full Text] [Related]
11. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
12. Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models.
Park SY; Piao Y; Jeong KJ; Dong J; de Groot JF
Mol Cancer Ther; 2016 Sep; 15(9):2187-97. PubMed ID: 27307601
[TBL] [Abstract][Full Text] [Related]
13. The Role Played by SLUG, an Epithelial-Mesenchymal Transition Factor, in Invasion and Therapeutic Resistance of Malignant Glioma.
Oh SJ; Ahn EJ; Kim O; Kim D; Jung TY; Jung S; Lee JH; Kim KK; Kim H; Kim EH; Lee KH; Moon KS
Cell Mol Neurobiol; 2019 Aug; 39(6):769-782. PubMed ID: 31011939
[TBL] [Abstract][Full Text] [Related]
14. Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas.
Coppola D; Balducci L; Chen DT; Loboda A; Nebozhyn M; Staller A; Fulp WJ; Dalton W; Yeatman T; Brem S
J Geriatr Oncol; 2014 Oct; 5(4):389-99. PubMed ID: 25220188
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.
Baker GJ; Yadav VN; Motsch S; Koschmann C; Calinescu AA; Mineharu Y; Camelo-Piragua SI; Orringer D; Bannykh S; Nichols WS; deCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
Neoplasia; 2014 Jul; 16(7):543-61. PubMed ID: 25117977
[TBL] [Abstract][Full Text] [Related]
16. Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma.
Ghazi SO; Stark M; Zhao Z; Mobley BC; Munden A; Hover L; Abel TW
J Neuropathol Exp Neurol; 2012 Aug; 71(8):729-40. PubMed ID: 22805776
[TBL] [Abstract][Full Text] [Related]
17. A 3-dimensional extracellular matrix as a delivery system for the transplantation of glioma-targeting neural stem/progenitor cells.
Hansen K; Müller FJ; Messing M; Zeigler F; Loring JF; Lamszus K; Westphal M; Schmidt NO
Neuro Oncol; 2010 Jul; 12(7):645-54. PubMed ID: 20156807
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-210-3p is transcriptionally upregulated by hypoxia induction and thus promoting EMT and chemoresistance in glioma cells.
Liu H; Chen C; Zeng J; Zhao Z; Hu Q
PLoS One; 2021; 16(7):e0253522. PubMed ID: 34197482
[TBL] [Abstract][Full Text] [Related]
19. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Tabatabai G; Frank B; Möhle R; Weller M; Wick W
Brain; 2006 Sep; 129(Pt 9):2426-35. PubMed ID: 16835250
[TBL] [Abstract][Full Text] [Related]
20. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
